08:53 AM EDT, 10/24/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that 67% of patients treated with its psoriasis drug candidate icotrokinra in a phase-3 study displayed overall rates of clear or almost clear skin by the end of 24 weeks, which was maintained through 52 weeks.

The company said that in patients treated with icotrokinra, 72% with scalp psoriasis and 85% with genital psoriasis demonstrated site-specific clear or almost clear skin at the end of 52 weeks.

Adverse and serious adverse event rates by the end of 52 weeks were similar to 16 weeks across treatment groups, the company said.

Johnson & Johnson ( JNJ ) shares were 0.2% lower in premarket trading.